{
  "PMC": "2762199",
  "DOI": "10.1100/tsw.2009.121",
  "PMID": "19802503",
  "PMCID": "PMC2762199",
  "title": "Erythropoietin, forkhead proteins, and oxidative injury: biomarkers and biology.",
  "year": 2009,
  "source_url": "https://europepmc.org/article/PMC/PMC2762199",
  "source": "MED",
  "abstract_text": "Oxidative stress significantly impacts multiple cellular pathways that can lead to the initiation and progression of varied disorders throughout the body. It therefore becomes imperative to elucidate the components and function of novel therapeutic strategies against oxidative stress to further clinical diagnosis and care. In particular, both the growth factor and cytokine erythropoietin (EPO), and members of the mammalian forkhead transcription factors of the O class (FoxOs), may offer the greatest promise for new treatment regimens, since these agents and the cellular pathways they oversee cover a range of critical functions that directly influence progenitor cell development, cell survival and degeneration, metabolism, immune function, and cancer cell invasion. Furthermore, both EPO and FoxOs function not only as therapeutic targets, but also as biomarkers of disease onset and progression, since their cellular pathways are closely linked and overlap with several unique signal transduction pathways. Yet, EPO and FoxOs may sometimes have unexpected and undesirable effects that can raise caution for these agents and warrant further investigations. Here we present the exciting as well as the complex role that EPO and FoxOs possess to uncover the benefits as well as the risks of these agents for cell biology and clinical care in processes that range from stem cell development to uncontrolled cellular proliferation.",
  "full_text": "ScientificWorldJournal ScientificWorldJournal TSWJ The Scientific World Journal 2356-6140 1537-744X TheScientificWorldJOURNAL 2762199 19802503 892314 10.1100/tsw.2009.121 Review Article Erythropoietin, Forkhead Proteins, and Oxidative Injury: Biomarkers and Biology Maiese Kenneth 1 2 3 4 5 * Hou Jinling 4 Chong Zhao Zhong 4 Shang Yan Chen 4 1 Division of Cellular and Molecular Cerebral Ischemia, Wayne State University School of Medicine, Detroit, MI, USA 2 Department of Neurology and Anatomy and Cell Biology, Wayne State University School of Medicine, Detroit, MI, USA 3 Barbara Ann Karmanos Cancer Institute, Wayne State University, School of Medicine, Detroit, MI, USA 4 Center for Molecular Medicine and Genetics, Wayne State University School of Medicine, Detroit, MI, USA 5 Institute of Environmental Health Sciences, Wayne State University School of Medicine, Detroit, MI, USA *Kenneth Maiese: kmaiese@med.wayne.edu Academic Editor: Sergi Ferre 2009 2 10 2009 9 1072 1104 12 8 2009 16 9 2009 17 9 2009 Copyright © 2009 Kenneth Maiese et al. 2009 This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Oxidative stress significantly impacts multiple cellular pathways that can lead to the initiation and progression of varied disorders throughout the body. It therefore becomes imperative to elucidate the components and function of novel therapeutic strategies against oxidative stress to further clinical diagnosis and care. In particular, both the growth factor and cytokine erythropoietin (EPO), and members of the mammalian forkhead transcription factors of the O class (FoxOs), may offer the greatest promise for new treatment regimens, since these agents and the cellular pathways they oversee cover a range of critical functions that directly influence progenitor cell development, cell survival and degeneration, metabolism, immune function, and cancer cell invasion. Furthermore, both EPO and FoxOs function not only as therapeutic targets, but also as biomarkers of disease onset and progression, since their cellular pathways are closely linked and overlap with several unique signal transduction pathways. Yet, EPO and FoxOs may sometimes have unexpected and undesirable effects that can raise caution for these agents and warrant further investigations. Here we present the exciting as well as the complex role that EPO and FoxOs possess to uncover the benefits as well as the risks of these agents for cell biology and clinical care in processes that range from stem cell development to uncontrolled cellular proliferation. aging Alzheimer’s disease angiogenesis apoptosis cancer cardiac diabetes erythropoietin forkhead transcription factors immune system ischemia neurodegeneration oxidative stress sirtuins stem cells vascular disease Wnt wingless National Institute of Environmental Health Sciences P30 ES06639 National Institute of Neurological Disorders and Stroke National Institute on Aging",
  "plain_text": "Oxidative stress significantly impacts multiple cellular pathways that can lead to the initiation and progression of varied disorders throughout the body. It therefore becomes imperative to elucidate the components and function of novel therapeutic strategies against oxidative stress to further clinical diagnosis and care. In particular, both the growth factor and cytokine erythropoietin (EPO), and members of the mammalian forkhead transcription factors of the O class (FoxOs), may offer the greatest promise for new treatment regimens, since these agents and the cellular pathways they oversee cover a range of critical functions that directly influence progenitor cell development, cell survival and degeneration, metabolism, immune function, and cancer cell invasion. Furthermore, both EPO and FoxOs function not only as therapeutic targets, but also as biomarkers of disease onset and progression, since their cellular pathways are closely linked and overlap with several unique signal transduction pathways. Yet, EPO and FoxOs may sometimes have unexpected and undesirable effects that can raise caution for these agents and warrant further investigations. Here we present the exciting as well as the complex role that EPO and FoxOs possess to uncover the benefits as well as the risks of these agents for cell biology and clinical care in processes that range from stem cell development to uncontrolled cellular proliferation."
}
